Highlights Kyowa Kirin Co. Ltd.

Equities

4151

JP3256000005

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
2,630 ^JPY	+0.23%		+0.80%	+10.97%

Apr. 08	U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	RE
Apr. 03	Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	Apr. 08	RE
Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March	Apr. 03	MT
Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	Apr. 02	CI
Japanese Shares Slip into Red Amid Profit-Taking; Tokyo Inflation Eyed	Mar. 25	MT
Kyowa Kirin to Allocate Over 84,000 Treasury Shares as Director, Officer Compensation	Mar. 25	MT
Kyowa Kirin's gene therapy most expensive US drug with $4.3 million price tag	Mar. 20	RE
US approves first gene therapy for children with rare genetic disease	Mar. 18	RE
US approves first gene therapy for rare genetic disease	Mar. 18	RE
Kyowa Kirin Co., Ltd. to Present Phase 2B Post-Hoc Analysis and Symposium At the American Academy of Dermatology Annual Meeting 2024	Mar. 08	CI
Kyowa Kirin Buys Back Nearly 3 Billion Yen of Shares	Mar. 05	MT
Japan's Nikkei closes at 34-year peak on dovish BOJ; tech shares soar	Feb. 08	RE
Japan's Nikkei leaps to 2-week high on tech stocks, yen boost	Feb. 07	RE
Kyowa Kirin's Profit Up 52% in Fiscal 2023	Feb. 07	MT
Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2024	Feb. 07	CI
Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2023, Payable on March 25, 2024; Provides Dividend Guidance for the Second Quarter of 2024	Feb. 07	CI
Kyowa Kirin Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024	Feb. 07	CI
Kyowa Kirin Co., Ltd. announces an Equity Buyback for 17,000,000 shares, representing 3.16% for KRW 40,000 million.	Feb. 07	CI
Kyowa Hakko Kirin Co., Ltd. authorizes a Buyback Plan.	Feb. 06	CI
Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema	Feb. 06	CI
Orchard Therapeutics Completes Sale to Japan's Kyowa Kirin	Jan. 24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kyowa Kirin Co. Ltd.

Equities

4151

JP3256000005

Highlights

Filters